NARATRIPTAN (naratriptan) by Hikma is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache, migraine. First approved in 2010.
Drug data last refreshed 21h ago
5-HT 1B/1D receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (including substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of naratriptan tablets for the treatment…
Worked on NARATRIPTAN at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
Sumatriptan and Naratriptan Pregnancy Registry